{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:26:59Z","timestamp":1786991219710,"version":"build-2736575974"},"reference-count":72,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010902","name":"Vanda Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010902","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jaad.2018.09.020","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:11:21Z","timestamp":1537834281000},"page":"756-764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["A systematic review of evidence-based treatments for prurigo nodularis"],"prefix":"10.1016","volume":"80","author":[{"given":"Azam A.","family":"Qureshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2018.09.020_bib1","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/bjd.12267","article-title":"Gender differences in chronic pruritus: women present different morbidity, more scratch lesions and higher burden","volume":"168","author":"St\u00e4nder","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1468-3083.2012.04481.x","article-title":"Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients","volume":"27","author":"Iking","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.09.020_bib3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2230.2006.02310.x","article-title":"Nodular prurigo: metabolic diseases are a common association","volume":"32","author":"Winhoven","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib4","first-page":"221","article-title":"Prurigo nodularis: picking the right treatment","volume":"64","author":"Saco","year":"2015","journal-title":"J Fam Pract"},{"key":"10.1016\/j.jaad.2018.09.020_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0190-9622(92)70006-2","article-title":"Demonstration by S-100 protein staining of increased numbers of nerves in the papillary dermis of patients with prurigo nodularis","volume":"26","author":"Harris","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2340\/00015555-2232","article-title":"Intraepidermal nerve fibre density is decreased in lesional and inter-lesional prurigo nodularis and reconstitutes on healing of lesions","volume":"96","author":"Bobko","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2018.09.020_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2133.2011.10306.x","article-title":"Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy","volume":"165","author":"Schuhknecht","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib8","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/exd.13343","article-title":"There is no functional small-fibre neuropathy in prurigo nodularis despite neuroanatomical alterations","volume":"26","author":"Pereira","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1034\/j.1600-0560.2000.027007359.x","article-title":"CGRP-immunoreactive nerves in prurigo nodularis\u2013an exploration of neurogenic inflammation","volume":"27","author":"Liang","year":"2000","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2018.09.020_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jdermsci.2010.03.020","article-title":"Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis","volume":"58","author":"Haas","year":"2010","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2018.09.020_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00128071-200405020-00003","article-title":"Prurigo: diagnosis and management","volume":"5","author":"Wallengren","year":"2004","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000245988","article-title":"Sequential combined therapy with thaiidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis","volume":"195","author":"Ferr\u00e1ndiz","year":"1997","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2018.09.020_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1440-0960.2005.00187.x","article-title":"Prurigo nodularis: a review","volume":"46","author":"Lee","year":"2005","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1600-0560.1998.tb01718.x","article-title":"Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal","volume":"25","author":"Liang","year":"1998","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2018.09.020_bib15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2018.09.020_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1684\/ejd.2010.1196","article-title":"Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigo","volume":"21","author":"Park","year":"2011","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib17","author":"Oxford Center for Evidence-based Medicine"},{"key":"10.1016\/j.jaad.2018.09.020_bib18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/archderm.136.6.807","article-title":"Double-blind, right\/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of prurigo nodularis","volume":"136","author":"Wong","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1067\/mjd.2001.110059","article-title":"Treatment of prurigo nodularis with topical capsaicin","volume":"44","author":"St\u00e4nder","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/tcrm.2006.2.2.213","article-title":"Treatment of pruritic diseases with topical calcineurin inhibitors","volume":"2","author":"St\u00e4nder","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jaad.2018.09.020_bib21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/09546630903386606","article-title":"An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis","volume":"21","author":"Saraceno","year":"2010","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2018.09.020_bib22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000355671","article-title":"Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial","volume":"227","author":"Siepmann","year":"2013","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2018.09.020_bib23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00105-003-0521-6","article-title":"Antipruritic effects of pimecrolimus and tacrolimus [in German]","volume":"54","author":"St\u00e4nder","year":"2003","journal-title":"Hautarzt"},{"key":"10.1016\/j.jaad.2018.09.020_bib24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neures.2004.07.005","article-title":"The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers","volume":"50","author":"Senba","year":"2004","journal-title":"Neurosci Res"},{"key":"10.1016\/j.jaad.2018.09.020_bib25","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/gut.52.9.1233","article-title":"Capsaicin and menthol in the treatment of itch and pain: recently cloned receptors provide the key","volume":"52","author":"Anand","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jaad.2018.09.020_bib26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2133.1996.tb01153.x","article-title":"Topical vitamin D3 (tacalcitol) for steroid-resistant prurigo","volume":"135","author":"Katayama","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib27","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1468-3083.2010.03865.x","article-title":"UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis","volume":"25","author":"Hammes","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.09.020_bib28","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1365-2133.2010.09858.x","article-title":"Excimer laser vs. clobetasol propionate 0\u00b705% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot","volume":"163","author":"Brenninkmeijer","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-0781.2008.00318.x","article-title":"Monochromatic excimer light (308 nm) in the treatment of prurigo nodularis","volume":"24","author":"Saraceno","year":"2008","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2018.09.020_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1600-0781.2008.00328.x","article-title":"Efficacy of UVA1 phototherapy in 230 patients with various skin diseases","volume":"24","author":"Rombold","year":"2008","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2018.09.020_bib31","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/pho.2008.2317","article-title":"Different applications of monochromatic excimer light in skin diseases","volume":"27","author":"Nistic\u00f2","year":"2009","journal-title":"Photomed Laser Surg"},{"key":"10.1016\/j.jaad.2018.09.020_bib32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2230.2009.03705.x","article-title":"Phototherapy of generalized prurigo nodularis","volume":"35","author":"Bruni","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1346-8138.2007.00360.x","article-title":"Narrow-band ultraviolet B phototherapy in patients with recalcitrant nodular prurigo","volume":"34","author":"Tamagawa-Mineoka","year":"2007","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2230.2003.01156_7.x","article-title":"Phototherapy in nodular prurigo","volume":"28","author":"Divekar","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib35","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/1523-1747.ep12458843","article-title":"Ultraviolet-B radiation suppresses mast cell degranulation induced by compound 48\/80","volume":"87","author":"Danno","year":"1986","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/00015550310022899","article-title":"Phototherapy reduces the number of epidermal and CGRP-positive dermal nerve fibres","volume":"84","author":"Wallengren","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2018.09.020_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000331577","article-title":"Thalidomide in 42 patients with prurigo nodularis hyde","volume":"223","author":"Andersen","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2018.09.020_bib38","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jaad.2015.09.039","article-title":"Thalidomide for the treatment of chronic refractory pruritus","volume":"74","author":"Sharma","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib39","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2133.2005.06747.x","article-title":"Thalidomide: dermatological indications, mechanisms of action and side-effects","volume":"153","author":"Wu","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib40","first-page":"814","article-title":"Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders","volume":"9","author":"Ladizinski","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib41","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2340\/00015555-0997","article-title":"Efficacy of thalidomide in the treatment of prurigo nodularis","volume":"91","author":"Taefehnorooz","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2018.09.020_bib42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1346-8138.2007.00260.x","article-title":"Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide","volume":"34","author":"Lan","year":"2007","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib43","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/archderm.140.7.845","article-title":"Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy","volume":"140","author":"Maurer","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib44","first-page":"194","article-title":"Management of thalidomide toxicity","volume":"1","author":"Ghobrial","year":"2003","journal-title":"J Support Oncol"},{"key":"10.1016\/j.jaad.2018.09.020_bib45","first-page":"769","article-title":"A case series of 48 patients treated with thalidomide","volume":"7","author":"Doherty","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib46","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1440-0960.2002.00593.x","article-title":"Thalidomide experience of a major Australian teaching hospital","volume":"43","author":"Crouch","year":"2002","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib47","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/ced.12365","article-title":"Prurigo nodularis: retrospective study of 13 cases managed with methotrexate","volume":"39","author":"Spring","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib48","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/jdv.14646","article-title":"Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases","volume":"32","author":"Klejtman","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.09.020_bib49","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1610-0387.2008.06745.x","article-title":"Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series","volume":"6","author":"Siepmann","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2018.09.020_bib50","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaad.2018.02.024","article-title":"Rapid improvement of prurigo nodularis with cyclosporine treatment","volume":"78","author":"Wiznia","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2340\/00015555-0553","article-title":"Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study","volume":"89","author":"St\u00e4nder","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2018.09.020_bib52","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","article-title":"Pharmacology and mechanism of action of pregabalin: the calcium channel \u03b12\u2013\u03b4 (alpha2\u2013delta) subunit as a target for antiepileptic drug discovery","volume":"73","author":"Taylor","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jaad.2018.09.020_bib53","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/jcpt.12005","article-title":"Treatment of prurigo nodularis with pregabalin","volume":"38","author":"Mazza","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jaad.2018.09.020_bib54","first-page":"433","article-title":"Amitriptyline as therapeutic and not symptomatic approach in the treatment of prurigo nodularis: a pilot study","volume":"141","author":"Zalaudek","year":"2006","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.09.020_bib55","doi-asserted-by":"crossref","first-page":"e10968","DOI":"10.1371\/journal.pone.0010968","article-title":"Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy","volume":"5","author":"St\u00e4nder","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2018.09.020_bib56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2340\/00015555-2780","article-title":"Role of substance P and its receptor neurokinin 1 in chronic prurigo: a randomized, proof-of-concept, controlled trial with topical aprepitant","volume":"98","author":"Ohanyan","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2018.09.020_bib57","unstructured":"Stander S, Kwon P, Luger T. A randomized, double-blind, placebo-controlled, study of the neurokinin-1 receptor (nk1-r) antagonist serlopitant in subjects with prurigo nodularis (PN). Paper presented at: American Academy of Dermatology Annual Meeting. March 3-7, 2017; Orlando, FL."},{"key":"10.1016\/j.jaad.2018.09.020_bib58","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2016.10.030","article-title":"Topical ketamine-amitriptyline-lidocaine for chronic pruritus: a retrospective study assessing efficacy and tolerability","volume":"76","author":"Lee","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib59","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2340\/00015555-2811","article-title":"Successful treatment of epidermal nevus-associated pruritus with topical ketamine\u2013amitriptyline\u2013lidocaine","volume":"98","author":"Jaller","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2018.09.020_bib60","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40257-016-0198-0","article-title":"Chronic pruritus in the absence of skin disease: pathophysiology, diagnosis and treatment","volume":"17","author":"Pereira","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib61","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archdermatol.2011.2918","article-title":"Treatment of refractory prurigo nodularis with lenalidomide","volume":"148","author":"Kanavy","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib62","first-page":"360","article-title":"Use of lenalidomide in treating refractory prurigo nodularis","volume":"12","author":"Liu","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib63","doi-asserted-by":"crossref","first-page":"e12451","DOI":"10.1111\/dth.12451","article-title":"Treatment of prurigo nodularis with lenalidomide","volume":"30","author":"Ossorio-Garc\u00eda","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2018.09.020_bib64","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1200\/JCO.2008.20.3737","article-title":"Erythema multiforme\/Stevens-Johnson syndrome\/toxic epidermal necrolysis in lenalidomide-treated patients","volume":"27","author":"Castaneda","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.09.020_bib65","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2141.2007.06698.x","article-title":"Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-na\u00efve patients undergoing front-line lenalidomide and dexamethasone therapy","volume":"138","author":"Niesvizky","year":"2007","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2018.09.020_bib66","first-page":"S39","article-title":"Mechanisms of action of gabapentin","volume":"153","author":"Taylor","year":"1997","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.jaad.2018.09.020_bib67","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1529-8019.2010.01314.x","article-title":"Therapeutic hotline: treatment of prurigo nodularis and lichen simplex chronicus with gabapentin","volume":"23","author":"Gencoglan","year":"2010","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2018.09.020_bib68","first-page":"85","article-title":"Gabapentin for the treatment of recalcitrant chronic prurigo nodularis","volume":"18","author":"Dereli","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2018.09.020_bib69","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.det.2018.02.003","article-title":"Prurigo nodularis and its management","volume":"36","author":"Zeidler","year":"2018","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2018.09.020_bib70","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti\u2013interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2018.09.020_bib71","author":"Trevi Therapeutics"},{"key":"10.1016\/j.jaad.2018.09.020_bib72","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4103\/0019-5154.117300","article-title":"Oral ketotifen and topical antibiotic therapy in the management of pruritus in prurigo nodularis: a randomized, controlled, single-blind, parallel study","volume":"58","author":"Sharma","year":"2013","journal-title":"Indian J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218326288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218326288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:48:38Z","timestamp":1759272518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218326288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0190962218326288"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.09.020","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of evidence-based treatments for prurigo nodularis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}